Recent Analysts’ Ratings Updates for Clearside Biomedical (CLSD)

Several brokerages have updated their recommendations and price targets on shares of Clearside Biomedical (NASDAQ: CLSD) in the last few weeks:

• 5/17/2025 – Clearside Biomedical was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 5/16/2025 – Clearside Biomedical had its “market outperform” rating reaffirmed by analysts at JMP Securities. They now have a $5.00 price target on the stock.
• 5/15/2025 – Clearside Biomedical had its price target lowered by analysts at Needham & Company LLC from $4.00 to $3.00. They now have a “buy” rating on the stock.
• 5/9/2025 – Clearside Biomedical was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 4/25/2025 – Clearside Biomedical was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 4/8/2025 – Clearside Biomedical had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $4.00 price target on the stock.
• 3/31/2025 – Clearside Biomedical had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
• 3/28/2025 – Clearside Biomedical had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $6.00 price target on the stock.
• 3/28/2025 – Clearside Biomedical had its price target lowered by analysts at Needham & Company LLC from $6.00 to $4.00. They now have a “buy” rating on the stock.

Clearside Biomedical Stock Performance

Shares of Clearside Biomedical stock traded up $0.01 on Monday, hitting $0.89. The company’s stock had a trading volume of 153,121 shares, compared to its average volume of 183,184. Clearside Biomedical, Inc. has a 1 year low of $0.70 and a 1 year high of $1.65. The firm has a fifty day moving average price of $0.88 and a 200-day moving average price of $0.95. The company has a market capitalization of $68.62 million, a price-to-earnings ratio of -1.97 and a beta of 2.11.

Clearside Biomedical (NASDAQ:CLSD) last issued its earnings results on Wednesday, May 14th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.01. The company had revenue of $2.33 million for the quarter, compared to analyst estimates of $0.20 million. As a group, analysts forecast that Clearside Biomedical, Inc. will post -0.48 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Investor s Fiduciary Advisor Network LLC acquired a new stake in shares of Clearside Biomedical in the fourth quarter valued at $32,000. Northern Trust Corp raised its stake in shares of Clearside Biomedical by 24.0% in the fourth quarter. Northern Trust Corp now owns 165,499 shares of the company’s stock valued at $157,000 after acquiring an additional 32,048 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Clearside Biomedical by 4.5% in the fourth quarter. Geode Capital Management LLC now owns 764,058 shares of the company’s stock valued at $726,000 after acquiring an additional 32,672 shares in the last quarter. 18.75% of the stock is currently owned by institutional investors and hedge funds.

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.